Nyxoah SA

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nyxoah reports mixed Q1 results, eyes strategic growth in 2023

Nyxoah's Q1 performance showed mixed results but with positive developments in the DREAM study and commercial rebound in Q2. The company aims for strategic growth in 2023 through market expansion and study advancements.

Nyxoah reports Q2 revenue growth, eyes FDA approval for U.S. market

Nyxoah's Q2 performance showed revenue growth and ongoing investments in market expansion. The company's strengths lie in Genio's features and upcoming milestones. Addressing challenges and seizing opportunities will be key for Nyxoah's future success.

Nyxoah reports Q3 revenue growth, eyes FDA approval by 2024

Nyxoah's Q3 performance reflects progress in key strategic areas, with a focus on patient-centric approaches and market expansion.
While facing challenges in managing expenses and regulatory timelines, the company is well-positioned for future growth and FDA approval by late 2024.
Opportunities lie in market expansion, partnerships, and innovative approaches to drive revenue growth and market penetration across regions.
Overall, Nyxoah's earnings call highlights a mix of strengths, challenges, and opportunities that shape its path towards leadership in the sleep disorder market.

Nyxoah SA reports robust Q4 sales and strategic 2024 plans

Nyxoah SA's Q4 2023 performance showcased strong sales growth and strategic accomplishments, setting the stage for future expansion.
While facing challenges in operating loss and cash burn, the company's financial position and upcoming milestones offer opportunities for growth.
Strategic partnerships and market positioning highlight Nyxoah's strengths in innovation and market differentiation.
Addressing market challenges and leveraging opportunities can drive Nyxoah's path towards profitability and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

REGULATED INFORMATION Nyxoah Reports Second Q uarter and First Half 2 02 3 Financial and Operating Results Mont-Saint-Guibert, Belgium – August 8 , 2023 10 : 0 5 pm CET / 4 : 0 5pm ET – Nyxoah SA ( Euronext Brussels/Nasdaq : NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2023. Recent Financial and Operating Highlights Presented 12-month efficacy data1 on the first 34 DREAM patients and safety data on all DREAM patients at SLEEP 2023, demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in-line with expectations.

Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results

Nyxoah to Release Second Quarter 2023 Financial Results on August 8 , 202 3

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

Nyxoah SA (NYXH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.29 per share a year ago.

Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates

Nyxoah S.A. (NASDAQ:NYXH ) Q1 2023 Earnings Conference Call May 16, 2023 4:30 PM ET Corporate Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - Chief Executive Officer Loic Moreau - Chief Financial Officer Conference Call Participants Jon Block - Stifel Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Suraj Kalia - Oppenheimer Operator Thank you for standing by, and welcome to Nyxoah's First Quarter 2023 Earnings Conference Call.

Nyxoah S.A. (NYXH) Q1 2023 Earnings Call Transcript

REGULATED INFORMATION   Nyxoah Reports First Quarter 2023 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.   Recent Financial and Operating Highlights  Completed all 115 implants in the DREAM U.S. pivotal trial, with 12-month data expected in the first quarter of 2024.

Nyxoah Reports First Quarter 2023 Financial and Operating Results

REGULATED INFORMATION May 12, 2023, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to Attend the Annual Shareholders '  Meeting of the Company to be Held on June 14 , 2023 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 14 , 2023 at 2:00   p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.

Invitation to Attend the Annual Shareholders' Meeting of the Company to be Held on June 14, 2023

Nyxoah Appoints Christoph Eig enmann as Chief Commercial Officer

Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer

Nyxoah to Release F irst Quarter 2023 Financial Results on Ma y 16 , 202 3

Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023

REGULATED INFOMATION Publication R elating to T ransparency N otification s Mont-Saint-Guibert (Belgium), April 20 , 202 3 , 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Together Partnership On April 18, 2023, Nyxoah received a transparency notification from Together Partnership following the crossing of the 10% threshold by Together Partnership on March 30, 2023.

Publication Relating to Transparency Notifications

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from its At-the-Market Equity Offering  Mont-Saint-Guibert, Belgium – April 13, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $3.0 million in gross proceeds pursuant to the Company's $50 million at-the-market ("ATM") program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The proceeds will be used for general corporate purposes.

Nyxoah Raises $3 Million from its At-the-Market Equity Offering

Nyxoah Raises $3 Million from an At-the-Market Equity Offering

Nyxoah Announces a $15 Million Private Placement Financing

Nyxoah S.A. (NASDAQ:NYXH ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Olivier Taelman - Chief Executive Officer Loïc Moreau - Chief Financial Officer Conference Call Participants Adam Maeder - PSC Jon Block - Stifel Suraj Kalia - Oppenheimer Operator Thank you for standing by.

Nyxoah S.A. (NYXH) Q4 2022 Earnings Call Transcript

Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023.

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference.

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones

Mont-Saint-Guibert, Belgium – February 22, 2023, 12:00pm CET / 6:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will host its inaugural Investor & Analyst Meeting on March 23, 2023, from 4:00pm to 7:00pm ET.

Nyxoah Announces Inaugural Investor & Analyst Meeting

Mont-Saint-Guibert, Belgium – January 9, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Mr. Daniel Wildman as an Independent Director to its Board of Directors*.

Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program

Nyxoah to Participate in the Piper Sandler 34 th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

Nyxoah S.A. (NASDAQ:NYXH ) Q3 2022 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jeremy Feffer - Vice President, Investor Relations Olivier Taelman - Chief Executive Officer Loïc Moreau - Chief Financial Officer Conference Call Participants Simran Kaur - Piper Sandler Jonathan Block - Stifel Nicolaus Ross Osborn - Cantor Fitzgerald Operator Good day.

News for Nyxoah SA Stock (NYXH)